Table 4

Incremental benefit of a boys and girls vaccination strategy against HPV 6,11,16,18 vs. girls-only vaccination (results presented in a steady state situation, at 50 and 100 years; results from base case analysis)
Gender Disease Annual number of HPV 6/11/16/18 cases Annual number of cases avoided with girls only vaccination Incremental number of cases avoided due to GNV (vs. girls only) Relative reduction in remaining burden: GNV vs. girls only (%)
At 50 years At 100 years At 50 years At 100 years At 50 years At 100 years
Female Genital warts 288,959 227,388 228,724 34,936 35,164 −56.7 −58.4
Cervical cancer 23,254 13,848 19,728 958 1,362 −10.2 −38.6
Vulvar cancer 2,702 873 2,286 67 157 −3.7 −37.8
Vaginal cancer 1,146 406 981 31 66 −4.2 −39.9
Anal cancer 2,929 821 2,330 80 258 −3.8 −43.0
Head/neck cancer 2,531 701 2,020 67 220 −3.7 −43.0
Total cancers 32,562 16,649 27,345 1,203 2,062 7.6 39.5
Male Genital warts 325,722 202,671 202,587 85,740 87,900 −69.7 −71.4
Penile cancers 1,091 93 197 156 542 −15.6 −60.6
Anal cancers 1,699 313 1,067 180 402 −13.0 −63.6
Head/neck cancers 12,707 2,555 8,203 1,449 2,967 −14.3 −65.9
Total cancers 15,497 2,961 9,467 1,784 3,911 14.2 64.9
Female + Male Genital warts 614,681 430,059 431,311 120,676 123,064 −65.4 −67.1
Total cancers 48,059 19,610 36,812 2,987 5,973 −10.5 −53.1

GNV, gender-neutral vaccination (boys and girls vaccination); HPV, human papillomavirus.

Marty et al.

Marty et al. BMC Cancer 2013 13:10   doi:10.1186/1471-2407-13-10

Open Data